For example, cilostazol, a drug that has been approved for peripheral vascular disease and has clear safety, has been proven to enhance proteasome activity and reduce tau pathology, making it the most promising candidate drug for direct clinical validation of AD. The gene discussed is MAPT; the disease is peripheral vascular disease.